Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) Holders
Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda ® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special...
TAMPA, Fla. , Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance...
Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities of...
Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda ® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway,...
Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression...
TAMPA, Fla. , Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. Â (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance...
Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory NPM1-mutated Acute Myeloid...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Routine medical appointments or cancer screening rates—an important aspect in increasing survival...
This week, the stock market faced a downturn as major indices struggled to maintain momentum. The S&P 500 (SPX), Dow Jones Industrial Average (DJI), and NASDAQ Composite (IXIC)Â all ended in the red, weighed...